Obagi Subject of Bidding War and 2 Stocks at 52-Week Peaks

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Obagi Medical Products (NASDAQ:OMPI): Closing price $

The potential acquisition of Obagi by Valeant Pharmaceuticals International (NYSE:VRX) and Merz Pharma Group, has turned into a bidding war, which is likely to affect Valeant’s guidance. Meanwhile, Obagi shares are not exactly being negatively impacted. Shares closed up 0.99 percent Thursday at $25.44, and have been traded between $10.70 and $25.50 the last 52 weeks.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business